Effects of high-isoflavone soy diet vs. casein protein diet and obesity on DMBA-induced mammary tumor development

Oncology Letters

Volumn 2, Issue 1, 2011, Pages 29-36

  Hakkak, Reza ^a   Shaaf, Saied ^a   Jo, Chan Hee ^a   MacLeod, Stewart ^a   Korourian, Soheila ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Breast cancer; Insulin growth factor 1; Obesity; Soy diet

Indexed keywords

CASEIN; DIMETHYLBENZ[A]ANTHRACENE; ISOFLAVONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; LEAN BODY WEIGHT; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN DIET; RAT; ZUCKER RAT;

EID: 78751504299     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.202     Document Type: Article

References (75)

1. American Cancer Society. Cancer Facts and Figures 2010.
2. Calle EE, Rodriguez C, Walker-Thurmond K. and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
3. Hakkak R, Korourian S, Shelnutt SR, Lensing S, Ronis MJ and Badger TM: Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. Cancer Epidemiol Biomarkers Prev 9: 113-117, 2000.
4. Kris-Etherton PM, Hecker KD, Bonanome A, et al: Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 113 (Suppl 9): 71-88, 2002.
5. Peeters PH, Keinan-Boker L, van der Schouw YT and GrobbeeDE: Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 77: 171-183, 2003.
6. Kelly GE, Nelson C, Waring MA, Joannou GE and Reeder AY: Metabolites of dietary (soya) isoflavones in human urine. Clin Chim Acta 223: 9-22, 1993.
7. Adlercreutz CH, Goldin BR, Gorbach SL, et al: Soybean phytoestrogen intake and cancer risk. J Nutr 125: S757-S770, 1995.
8. ridley DS, Kettering JD, Slater JM and Nutter RL: Modification of spontaneous mammary tumors in mice fed different sources of protein, fat and carbohydrate. Cancer Lett 19: 133-146, 1983.
9. Hargreaves DF, Potten CS, Harding C, et al: Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 84: 4017-4024, 1999.
10. Travis RC, Allen NE, Appleby PN, Spencer EA, Roddam AW and Key TJ: A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer 122: 705-710, 2008.
11. Cohen LA, Zhao Z, Pittman B and Scimeca JA: Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis. Carcinogenesis 21: 929-935, 2000.
12. Constantinou AI, Lantvit D, Hawthorne M, Xu X, vanBreemenRB and Pezzuto JM: Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer41: 75-81, 2001.
13. Gallo D, Giacomelli S, Cantelmo F, et al: Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res Treat 69: 153-164, 2001.
14. Jin Zand MacDonald RS: Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 132: 3186-3190, 2002.
15. Ueda M, Niho N, Imai T, et al: Lack of significant effects of genistein on the progression of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. Nutr Cancer 47: 141-147, 2003.
16. Hewitt AL. and Singletary KW: Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model. Cancer Lett 192: 133-143, 2003.
17. Shao ZM, Wu J, Shen ZZ. and Barsky SH: Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58: 4851-4857, 1998.
18. Allred CD, Allred KF, Ju YH, et al: Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis25: 211-218, 2004.
19. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR and Helferich WG: Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 131: 2957-2962, 2001.
20. Bruning PF, van Doorn J, Bonfrer JM, et al: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62: 266-270, 1995.
21. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, PageD and Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Cancer Res Treat 47: 111-120, 1998.
22. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998.
23. Krajcik RA, Borofsky ND, Massardo S and Orentreich NI: Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1566-1573, 2002.
24. Muti P, Quattrin T, Grant BJ, et al: Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11: 1361-1368, 2002.
25. Peyrat JP, Bonneterre J, Hecquet B, et al: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer Prev 29A: 492-497, 1993.
26. Toniolo P, Bruning PF, Akhmedkhanov A, et al: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828-832, 2000.
27. Yu H, Jin F, Shu XO, et al: Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11: 705-712, 2002.
28. Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244, 2000.
29. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489, 2000.
30. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, deJong-BakkerM and Nooijen WJ: Insulin resistance and breast-cancer risk. Int J Cancer 52: 511-516, 1992.
31. Kaaks R, Lundin E, Rinaldi S, et al: Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13: 307-316, 2002.
32. Tartaglia LA, Dembski M, Weng X, et al: Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995.
33. Chua SC Jr, Chung WK, Wu-Peng XS, et al: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271: 994-996, 1996.
34. Zucker L. and Zucker TF: Fatty, a new mutation in the rat. J Heredity 52: 275-278, 1961.
35. Zucker TF and Zucker LM: Fat accretion and growth in the rat. J Nutr 80: 6-19, 1963.
36. Zucker LM: Fat mobilization in vitro and in vivo in the genetically obese Zucker rat 'Fatty'. J Lipid Res 13: 234-243, 1972.
37. Bray GA, York DA and Fisler JS: Experimental obesity: a homeostatic failure due to defective nutrient stimulation of the sympathetic nervous system. Vitam Horm 45: 1-125, 1989.
38. Bray GA: The Zucker-fatty rat: a review. Fed Proc 36: 148-153, 1977.
39. Hakkak R, Holley AW, MacLeod S, et al: Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female Zucker rats. Breast Cancer Research 7: R627-R633, 2005.
40. Hakkak R, MacLeod S, Shaaf S, et al: Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in an ovariectomized Zucker rat model. Int J Oncol 30: 557-563, 2007.
41. Tovar AR, Torre-Villavazo I, Ochoa M, et al: Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 46: 1823-1832, 2005.
42. Trujillo J, Ramirez V, Perez J, et al: Renal protection by a soy diet in obese Zucker rats is associated with restoration of nitric oxide generation. Am J Physiol Renal Physiol 288: F108-F116, 2005.
43. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA and ShayN: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine raw 264.7 cells. J Nutr 133: 1238-1243, 2003.
44. Pathak DR and Whittemore AS: Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol 135: 153-168, 1992.
45. Peacock SL, White E, Daling JR, Voigt LF and Malone KE: Relation between obesity and breast cancer in young women. Am J Epidemiol 149: 339-346, 1999.
46. Weiderpass E, Braaten T, Magnusson C, et al: A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13: 1121-1127, 2004.
47. Simmen RC, Eason RR, Till SR, et al: Inhibition of NMU-induced mammary tumorigenesis by dietary soy. Cancer Lett 224: 45-52, 2005.
48. Hsieh CY, Santell RC, Haslam SZ. and Helferich WG: Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 58: 3833-3838, 1998.
49. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J and Day NE: Dietary effects on breast-cancer risk in singapore. Lancet 337: 1197-1200, 1991.
50. Wu AH, Yu MC, Tseng CC and Pike MC: Epidemiology of soy exposures and breast cancer risk. Br J Cancer 98: 9-14, 2008.
51. Trock BJ, Hilakivi-Clarke L. and Clarke R: Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98: 459-471, 2006.
52. Messina MJ: Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 61: 117-131, 2003.
53. Lee SA, Shu XO, Li H, et al: Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr 89: 1920-1926, 2009.
54. Enderlin CA, Coleman EA, Stewart CB and Hakkak R: Dietary soy intake and breast cancer risk. Oncol Nurs Forum 36: 531-539, 2009.
55. Wu Y, Cui K, Miyoshi K, et al: Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63: 4384-4388, 2003.
56. Arjmandi BH, Khalil DA, Smith BJ, et al: Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 88: 1048-1054, 2003.
57. Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME. and Arjmandi BH: Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism. J Nutr 132: 2605-2608, 2002.
58. Sanderson M, Shu XO, Yu H, et al: Insulin-like growth factor-I, soy protein intake, and breast cancer risk. Nutr Cancer 50: 8-15, 2004.
59. Wangen KE, Duncan AM, Merz-Demlow BE, et al: Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocr Metab 85: 3043-3048, 2000.
60. Hakkak R, Holley AW, Bunn RC, Winters A and MacLeod S: Effects of obesity on serum insulin growth factor 1 (IGF-1) levels in lean and obese female Zucker rats following DMBA treatment. FASEB J 19: A993, 2005.
61. Allen NE, Appleby PN, Davey GK, Kaaks R, Rinaldi S and Key TJ: The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiol Biomarkers Prev 11: 1441-1448, 2002.
62. Devine A, Rosen C, Mohan S, Baylink D and Prince RL: Effects of zinc and other nutritional factors on insulin-like growth factorI and insulin-like growth factor binding proteins in postmenopausal women. Am J Clin Nutr 68: 200-206, 1998.
63. Giovannucci E, Pollak M, Liu Y, et al: Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 12: 84-89, 2003.
64. Gunnell D, Oliver SE, Peters TJ, et al: Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 88: 1682-1686, 2003.
65. Heald AH, Cade JE, Cruickshank JK, Anderson S, White A and Gibson JM: The influence of dietary intake on the insulin-like growth factor (IGF) system across three ethnic groups: a population-based study. Public Health Nutr 6: 175-180, 2003.
66. Holmes MD, Pollak MN, Willett WC and Hankinson SE: Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 852-861, 2002.
67. Ma J, Giovannucci E, Pollak M, et al: Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst 93: 1330-1336, 2001.
68. Mucci LA, Tamimi R, Lagiou P, et al: Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJUInt 87: 814-820, 2001.
69. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N and Yasuda K: Dietary soy and fats in relation to serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels in premenopausal Japanese women. Nutr Cancer 45: 185-189, 2003.
70. Probst-Hensch NM, Wang H, Goh VH, Seow A, Lee HP and Yu MC: Determinants of circulating insulin-like growth factorI and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers Prev 12: 739-746, 2003.
71. Signorello LB, Kuper H, Lagiou P, et al: Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 9: 173-178, 2000.
72. Vrieling A, Voskuil DW, Bueno-de-Mesquita HB, et al: Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands. Cancer Causes Control 15: 787-796, 2004.
73. Rinaldi S, Toniolo P, Muti P, et al: IGF-I, IGFBP-3 and breast cancer in young women: a pooled re-analysis of three prospective studies. Eur J Cancer Prev 14: 493-496, 2005.
74. Bohlke K, Cramer DW, Trichopoulos D and Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9: 570-573, 1998.
75. Woodside JV, Campbell MJ, Denholm EE, et al: Short-term phytoestrogen supplementation alters insulin-like growth factor profile but not lipid or antioxidant status. J Nutr Biochem 17: 211-215, 2006.